Back to Search Start Over

Treatment of refractory diffuse large B-cell lymphoma by chidamide combined with autologous stem cell transplantation: a case report.

Authors :
Wu P
Ma T
Chen Y
Wang F
Chen Y
Gao J
Zhou Z
Jia Y
Source :
Anti-cancer drugs [Anticancer Drugs] 2021 Sep 01; Vol. 32 (8), pp. 886-889.
Publication Year :
2021

Abstract

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin's lymphoma, with certain DLBCLs affecting specific anatomic sites, such as primary cutaneous DLBCL, leg type and intravascular large B-cell lymphoma. However, the occurrence of secondary cutaneous involvement in DLBCL while patients are undergoing regular chemotherapy is rare. In this study, we reported a case of refractory diffuse large B-cell lymphoma with cutaneous involvement that achieved complete remission for more than 4 years with epigenetic regulation of chidamide in combination with chemotherapy and autologous hematopoietic stem cell transplantation including a pretreatment regimen containing chidamide.<br /> (Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.)

Details

Language :
English
ISSN :
1473-5741
Volume :
32
Issue :
8
Database :
MEDLINE
Journal :
Anti-cancer drugs
Publication Type :
Academic Journal
Accession number :
34145178
Full Text :
https://doi.org/10.1097/CAD.0000000000001093